Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDXK | O00764 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.31 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28988100 | 0.72 | CHRNB2 (0.32) | — | |
| SCHEMBL30474091 | 0.68 | MEN1 (0.30) | ALDH1A1MEN1LMNAKMT2A | |
| SCHEMBL30326165 | 0.68 | LMNA (0.32) | HPGDLMNA | |
| SCHEMBL24469506 | 0.66 | ACVRL1 (0.38) | PDXK | |
| SCHEMBL29606087 | 0.66 | ACVRL1 (0.38) | PDXK | |
| SCHEMBL28988104 | 0.65 | PDXK (0.47) | PDXKKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL30500628 | 0.64 | PDXK (0.50) | PDXKKDM4EALDH1A1HPGDMEN1 | |
| SCHEMBL6844790 | 0.64 | PDXK (0.50) | PDXKKDM4EALDH1A1HPGDLMNA | |
| SCHEMBL16177071 | 0.64 | PDXK (0.50) | PDXKKDM4EALDH1A1HPGDMEN1 | |
| SCHEMBL30058522 | 0.63 | PDXK (0.48) | PDXKKDM4EALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115989224-B | Plasma kallikrein inhibitors | 默沙东有限责任公司 | 2025-02-25 | — | — | CN | disclosed |
| US-20230286958-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-09-14 | — | — | US | disclosed |
| CN-115989224-A | Plasma kallikrein inhibitors | 默沙东有限责任公司 | 2023-04-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230286958-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, SERPINE1, KLK5 | PDXK 111/4885KDM4E 1074/4885ALDH1A1 1701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.